6909-62-2 Usage
Uses
Used in Pharmaceutical Industry:
Demanyl phosphate is used as a precursor for the synthesis of acetylcholine, a neurotransmitter that plays a vital role in cognitive functions and memory. It is used in the development of drugs targeting neurological disorders and cognitive impairments.
Used in Neurological Applications:
Demanyl phosphate is used as a neuroprotective agent for the treatment of neurological disorders such as Alzheimer's disease, Parkinson's disease, and other cognitive impairments. It helps in enhancing the synthesis of acetylcholine, which is essential for maintaining cognitive functions and memory.
Used in Cognitive Enhancement:
Demanyl phosphate is used as a cognitive enhancer to improve memory, focus, and overall cognitive performance. It is used in the development of nootropic supplements and cognitive-enhancing drugs to support brain health and cognitive function.
Check Digit Verification of cas no
The CAS Registry Mumber 6909-62-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,0 and 9 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 6909-62:
(6*6)+(5*9)+(4*0)+(3*9)+(2*6)+(1*2)=122
122 % 10 = 2
So 6909-62-2 is a valid CAS Registry Number.
InChI:InChI=1/C4H12NO4P/c1-5(2)3-4-9-10(6,7)8/h3-4H2,1-2H3,(H2,6,7,8)
6909-62-2Relevant academic research and scientific papers
Structurally diverse low molecular weight activators of the mammalian pre-mRNA 3′ cleavage reaction
Liu, Min Ting,Nagre, Nagaraja N.,Ryan, Kevin
, p. 834 - 841 (2014/01/23)
The 3′ end formation of mammalian pre-mRNA contributes to gene expression regulation by setting the downstream boundary of the 3′ untranslated region, which in many genes carries regulatory sequences. A large number of protein cleavage factors participate in this pre-mRNA processing step, but chemical tools to manipulate this process are lacking. Guided by a hypothesis that a PPM1 family phosphatase negatively regulates the 3′ cleavage reaction, we have found a variety of new small molecule activators of the in vitro reconstituted pre-mRNA 3′ cleavage reaction. New activators include a cyclic peptide PPM1D inhibitor, a dipeptide with modifications common to histone tails, abscisic acid and an improved l-arginine β-naphthylamide analog. The minimal concentration required for in vitro cleavage has been improved from 200 μM to the 200 nM-100 μM range. These compounds provide unexpected leads in the search for small molecule tools able to affect pre-mRNA 3′ end formation.
